KRAS and lung adenocarcinoma: Homozygous loss of MAP2K4 often co‐occurred with TP53 (encoding p53) and KRAS mutations in lung adenocarcinomas, suggesting there are specific genetic backgrounds in which MKK4 functions as a tumor suppressor.